Life Diagnostics, Inc. adds a new leucine-rich alpha-2-glycoprotein-1 (LRG1) assay to its extensive lineup of SPARCL assays. The new assay was developed for cats (LRG-SP-8).
Leucine-rich alpha-2-glycoprotein-1 (LRG1) is a 50 kDa protein that is primarily expressed in liver. In humans, it is a positive acute phase reactant; serum levels are elevated during chronic inflammatory diseases and infections. Research at Life Diagnostics indicates that LRG1 is also a positive acute phase reactant in cats.
The new cat LRG1 assay joins SPARCL based monkey and human LRG1 assays in the Life Diagnostics lineup.
In addition to fully developed and tested SPARCL assay kits, Life Diagnostics provides HRP and acridan conjugation services for the development of new SPARCL assays. Please visit the Life Diagnostics SPARCL Assay web page for more information.
